Upstream Bio, Inc. (UPB)
5.375
+0.20
(+3.97%)
USD |
NASDAQ |
Sep 25, 16:00
5.375
0.00 (0.00%)
After-Hours: 19:59
Upstream Bio Research and Development Expense (Annual) : 136.81M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 136.81M |
| December 31, 2024 | 62.97M |
| Date | Value |
|---|---|
| December 31, 2023 | 31.80M |
| December 31, 2022 | 18.66M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Sutro Biopharma, Inc. | 166.42M |
| Compass Therapeutics, Inc. | 55.69M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |